Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for DVT Prophylaxis in Colorectal Cancer Surgery
NCT05303818Phase 4Unknown
- Sponsor
- Hospital do Servidor Público Estadual
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivaroxaban in deep vein thrombosis (DVT) and venous thromboembolism (VTE), sponsored by Hospital do Servidor Público Estadual. Primary endpoint: Deep venous thrombosis and embolic pulmonary disease. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
deep vein thrombosis (DVT)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05303818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05303818.